Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more
Hebei Changshan Biochem Pharma - Asset Resilience Ratio
Hebei Changshan Biochem Pharma (300255) has an Asset Resilience Ratio of -0.03% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Hebei Changshan Biochem Pharma's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hebei Changshan Biochem Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-1.20 Million | -0.03% |
| Total Liquid Assets | CN¥-1.20 Million | -0.03% |
Asset Resilience Insights
- Limited Liquidity: Hebei Changshan Biochem Pharma maintains only -0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Hebei Changshan Biochem Pharma Industry Peers by Asset Resilience Ratio
Compare Hebei Changshan Biochem Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF |
Biotechnology | 25.67% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Exicure Inc
NASDAQ:XCUR |
Biotechnology | 0.00% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Hebei Changshan Biochem Pharma (None–None)
The table below shows the annual Asset Resilience Ratio data for Hebei Changshan Biochem Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||